Literature DB >> 3011895

Properties of a specific interleukin 1 (IL 1) receptor on human Epstein Barr virus-transformed B lymphocytes: identity of the receptor for IL 1-alpha and IL 1-beta.

K Matsushima, T Akahoshi, M Yamada, Y Furutani, J J Oppenheim.   

Abstract

The properties of specific human interleukin 1 (IL 1) receptors on human Epstein Barr virus-transformed B lymphocytes (EBV-B) were studied. Purified human IL 1-beta from a myelomonocytic cell line (THP-1) was labeled with 125I by the Bolton-Hunter method without detectable loss of biological activity. Among four EBV-B cell lines tested, a pre-B cell type (VDS-O) specifically bound the highest amount of 125I-IL 1-beta. Maximal binding was reached within 20 min at 4 degrees C. Scatchard plot analysis of the binding of 125I-IL 1-beta to VDS-O cells yielded a Kd (dissociation constant) of 2.4 to 5.9 X 10(-10) M with 110 to 220 binding (receptor) sites/cell. The binding of 125I-IL 1-beta to VDS-O cells was also inhibited by F(ab)'2 fragments of anti-human IL 1 and recombinant human IL 1-alpha, as well as by unlabeled human IL 1-beta but not by recombinant lymphotoxin, recombinant tumor necrosis factor, or phorbol myristic acid, suggesting that IL 1-alpha and IL 1-beta bind specifically to the same receptor. The m.w. of IL 1 receptor on human EBV-B cells was estimated to be 60,000 by both the chemical cross-linking method and high pressure liquid chromatography (HPLC) gel filtration analysis of receptor extracted from membrane enriched fraction by a non-ionic detergent (CHAPS). The isoelectric point of solubilized human IL 1 receptor was 7.3 on HPLC chromatofocusing. The evidence of existence of IL 1 receptor on human EBV-B cells additionally supports the hypothesis that IL 1 may be an autocrine signal for these cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011895

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  The interleukin-1 receptor in Raji human B-lymphoma cells. Molecular characterization and evidence for receptor-mediated activation of gene expression.

Authors:  R Horuk; J A McCubrey
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

2.  Interleukin-1 receptor mRNA expression in activated bovine leukocytes in vitro.

Authors:  P W Yu; L A Schuler; C J Czuprynski
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

3.  Interleukin 1-induced calcium signalling in chondrocytes requires focal adhesions.

Authors:  L Luo; T Cruz; C McCulloch
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

4.  Two high-affinity interleukin 1 receptors represent separate gene products.

Authors:  R Chizzonite; T Truitt; P L Kilian; A S Stern; P Nunes; K P Parker; K L Kaffka; A O Chua; D K Lugg; U Gubler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 5.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

6.  Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro.

Authors:  C P Maury; L C Andersson; A M Teppo; S Partanen; E Juvonen
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

7.  Species-specific TNF induction of thymocyte proliferation.

Authors:  M J Ehrke; R L Ho; K Hori
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

Authors:  Janice P Dutcher; Donna Neuberg; Michael B Atkins; William J Tester; Scott Wadler; James A Stewart; Abraham Chachoua; Lynn M Schuchter
Journal:  J Interferon Cytokine Res       Date:  2014-01-16       Impact factor: 2.607

9.  Transport of interleukin-1 across cerebromicrovascular endothelial cells.

Authors:  R A Skinner; R M Gibson; N J Rothwell; E Pinteaux; J I Penny
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

10.  Azadirachtin interacts with the tumor necrosis factor (TNF) binding domain of its receptors and inhibits TNF-induced biological responses.

Authors:  Maikho Thoh; Pankaj Kumar; Hampathalu A Nagarajaram; Sunil K Manna
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.